Antibody-Drug Conjugates (ADCs) are a class of biopharmaceuticals that combine monoclonal antibodies with cytotoxic drugs to treat cancer. ADCs consist of three main components: a monoclonal antibody that binds to specific proteins on cancer cells, a chemical linker that attaches the antibody to the drug, and the drug payload, which is released inside the cancer cell to induce cell death. Unlike conventional chemotherapy, ADCs are designed to target cancer cells specifically, minimizing damage to healthy cells.
The success of ADCs depends on the careful selection and rational design of several key elements: the target antigen, the antibody, the linker, the payload, and the methods used to conjugate these components. Among these, the choice of targeting antibody, linker design, conjugation techniques, and the evaluation of preclinical and clinical efficacy are particularly crucial for developing effective ADC therapies.
To meet the needs of ADCs development, BroadPharm can provide: